Leadartis to present at BioSpain 2016 in Bilbao


Leadartis will participate in BioSpain 2016 to be held in Bilbao, Spain (September 28-30th). BioSpain was chosen to present our business to the investment community since is the most important biotechnology event in Spain and one of the most important internationally. LeadArtis will announce its business strategy at the highly regarded investment forum.

LeadArtis is the leading company bringing to the market cancer immunotherapy products exploiting the antibody engineering trimerbody™ technology. Existing immune-checkpoint blockers marketed or in development are conventional monoclonal antibodies (mAbs); comparatively, engineered antibody technologies are strongly positioned and shortly will become preferred. The added value of the trimerbody format is multivalence /multispecificity, small size & ease of manufacturing to generate more effective immunooncology compounds.

BioSpain is organized by ASEBIO (Spanish association of biotechnology companies) and co-organized by several local institutions including the regional government and biopharmaceutical companies. The Congress includes a trade exhibition, a partnering event, an investment forum, plenary recessions and conferences on varied subjects with international speakers. This year the Congress has hosted over 2000 participants and 800 companies and institutions from 40 countries, including Portugal, Spain, France, the United Kingdom, Canada, Colombia, Mexico, Russia and India.

Latest News

LeadArtis participates in the fourth Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting in London (UK)

The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom....

LeadArtis discloses ATTACK, a novel bispecific T cell-recruiting antibody approach for cancer immunotherapy

LeadArtis´scientists, in collaboration with other prime...

Leadartis successfully accomplishes the TERET project

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...